Scholar Rock Holding




MarketCap US

US United States


Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.


Scholar Rock was founded in 2014 by PureTech Health, an advanced biotherapeutics company. Scholar Rock was established as an independent biopharmaceutical company focused on developing therapeutics targeting pathways that regulate the balance between cell and muscle growth and remodeling.

To discover and develop medicines that significantly improve the lives of people with diseases of muscle, cell, and nerve growth and differentiation.

Scholar Rock seeks to become a leader in the development of innovative medicines for muscle and cell growth and differentiation.

Key Team

Ms. Junlin Ho J.D. (Gen. Counsel & Corp. Sec.)

Ms. Erin Moore (Sr. VP of Fin.)

Mr. Ryan Iarrobino (Sr. VP of Clinical Devel. & Operations)

Dr. Jing L. Marantz M.B.A., M.D., Ph.D. (Chief Medical Officer)

Ms. Caryn Parlavecchio (Chief HR Officer)

Ms. Lisa Amaya Price (Sr. VP of HR)

Dr. George G. Nomikos M.D., Ph.D. (Sr. VP of Medical & Clinical Sciences and Head of Muscle Therapeutic Area)

Recognition and Awards
Scholar Rock has been awarded the BIO Award for Innovation, and has also been recognized as a Top 10 Biotech Company by Inc. Magazine.

Scholar Rock Holding
Leadership team

Mr. Edward H. Myles M.B.A., MBA (CFO, COO & Treasurer)

Dr. Jay T. Backstrom M.D., M.P.H. (Pres, CEO & Director)

Ms. Catherine Hu (VP of Investor Relations & Corp. Communications)

Products/ Services
Biopharma, Biotechnology, Medical, Therapeutics
Number of Employees
100 - 500
Cambridge, Massachusetts, United States
Company Registration
SEC CIK number: 0001727196
20M - 100M
Traded as
Social Media

Businessabc provides a global business, SMEs wiki directory blockchain, NFTs, AI powered marketplace for businesses worldwide.

Follow Us
Produced by
In collaboration with

Copyright 2023 © Businessabc powered by ztudium